Tumor Infiltrating Lymphocyte Biology
Solutions Accelerated by IsoPlexis
- Combination Cancer Therapies
Apply TILs PSI as a correlate to response in combination checkpoint therapy1
Uncover the polyfunctional T cell subsets which correlate to in vivo activity and identify biomarker correlates to response in solid tumor therapies.
Uncovering the ability to predict adaptive resistance to glioblastoma and other solid tumors to targeted inhibitor therapeutics.
IsoPlexis’ PSI successfully stratifies patient responders and non-responders
Polyfunctional strength uniquely correlated with response, while histology and serum cytokine measurements did not
Single cell polyfunctionality shows positive correlation with clinical anti-tumor responses after treatment. Samples from responders have 9x more polyfunctional cells than non-responders, and 40x higher polyfunctional strength (p= 0.0294).
Individual cells secreted various combinations of effector cytokines (Granzyme B, IFN-γ, MIP-1α, Perforin and TNF-α) associated with anti-tumor immunity.1